CREALOGIX Group — Forecasts updated for acquisition document

CREALOGIX (SW: CLXN)

Last close As at 21/11/2024

124.50

0.00 (0.00%)

Market capitalisation

174m

More on this equity

Research: TMT

CREALOGIX Group — Forecasts updated for acquisition document

In January, CREALOGIX announced the acquisition of Innofis, a Barcelona-based digital banking business, to expand its core digital banking business into the Middle Eastern markets. No financial information on the transaction was provided at the time and, given the size of the deal, the company was required to produce a prospectus, which has revealed all the relevant information. The value of the deal is c CHF39m, which translates to c 3.6x trailing revenues or 9.3x EBITDA. On our updated forecasts, the deal is 11% earnings enhancing (undiluted basis) in FY19.

Analyst avatar placeholder

Written by

TMT

CREALOGIX Group

Forecasts updated for acquisition document

Prospectus

Software & comp services

17 May 2018

Price

CHF163

Market cap

CHF225m

CHF1.192/€

Net cash (CHFm) at 31 December 2017

15.4

Shares in issue

1.38m

Free float

32%

Code

CLXN

Primary exchange

Switzerland

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(1.8)

(5.1)

43.7

Rel (local)

(1.3)

2.4

39.6

52-week high/low

CHF178

CHF114.5

Business description

CREALOGIX Group provides digital banking technology solutions to banks, wealth managers and other financial services companies. The company’s suite of solutions includes online and mobile banking, digital payments, digital learning and security.

Next events

Final results

18 September 2018

Analyst

Richard Jeans

+44 (0)20 3077 5700

CREALOGIX Group is a research client of Edison Investment Research Limited

In January, CREALOGIX announced the acquisition of Innofis, a Barcelona-based digital banking business, to expand its core digital banking business into the Middle Eastern markets. No financial information on the transaction was provided at the time and, given the size of the deal, the company was required to produce a prospectus, which has revealed all the relevant information. The value of the deal is c CHF39m, which translates to c 3.6x trailing revenues or 9.3x EBITDA. On our updated forecasts, the deal is 11% earnings enhancing (undiluted basis) in FY19.

Year
end

Revenue (CHFm)

PBT*
(CHFm)

EPS*
(CHF)

DPS
(CHF)

P/E
(x)

Yield
(%)

06/16

63.3

2.2

1.65

0.00

99.0

N/A

06/17

74.9

5.0

2.67

0.50

61.1

0.3

06/18e

88.1

10.0

5.72

1.00

28.5

0.6

06/19e

102.4

14.7

7.62

1.50

21.4

0.9

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Cost of Innofis

The prospectus reveals that CREALOGIX is issuing 170k shares and paying CHF12m in cash for Innofis, which had CHF1.4m in cash on its balance sheet as at 31 December 2017. There is no deferred consideration. Transaction costs are estimated at CHF0.5m. In the year ended December, Innofis generated revenue of CHF10.8m, up 44%, and an operating profit of CHF4.1m for a margin of 37.7%.

Forecasts: Innofis added

We have increased our revenue forecasts by 7% in FY18 and 14% in each of FY19 and FY20 and our EBITDA forecasts increase by 20%, 35% and 34%, respectively. Given the significantly higher operating margins at Innofis, we forecast operating margins to rise by c 250bp. Our adjusted EPS (undiluted basis) increases by 10%, 12% and 14% in the respective years, tempered by the higher share count. Given the rise in the share price, convertible bonds have been actively converting. Hence we now forecast the group to end FY18 with net cash at CHF19.2m (previously CHF18.4m), which rises to CHF28.0m a year later (CHF23.5m). Assuming that the remaining bonds convert will add CHF10.6m of net cash to the balance sheet.

Valuation: 10% growth with 20% operating margins would imply significant upside

The acquisition creates a range of opportunities for management to accelerate revenue growth and boost margins. A discounted cash flow (DCF) scenario incorporating 10% organic revenue CAGR over 2017-27 fading thereafter to 2%, operating margins tapering up to a level of 20% from FY22, along with a 9% WACC, would suggests a valuation of CHF259, 59% above the current share price. Assuming a 25% margin target, all other things being equal, would lift the valuation to CHF317. These valuations are after the dilution impact from the outstanding convertible bonds.

Updated prospectus information on Innofis transaction

CREALOGIX has acquired Innofis from David Moreno, its CEO, founder and 96.5% shareholder, and the minority shareholders. CREALOGIX is issuing 170k shares and paying CHF12m in cash for Innofis, and there is no deferred consideration. Transaction costs are estimated at CHF0.5m. That puts a valuation on the deal at CHF40.7m based on the CHF166 issue price, or CHF39.3m after deducting the CHF1.4m in cash that Innofis had on its balance sheet as at 31 December 2017. There is a lock-in clause whereby the vendors are unable to sell their shares for at least three years. Please refer to our January update note for our initial analysis on the Innofis transaction.

Exhibit 1: Innofis’s selected financial history

€000s

FY15

FY16

FY17

Revenues

5,473

6,786

9,770

Change (%)

24.0

44.0

Operating profit

2,470

2,819

3,684

Operating margin (%)

45.1

41.5

37.7

Source: CREALOGIX Group

CREALOGIX’s capital structure

Following the transaction, CREALOGIX retains a strong financial position, as shown in Exhitibt 2, with a net cash position and no bank debt. Further, CREALOGIX’s convertibles bonds have been actively converting, with CHF10.6m nominal outstanding as at 9 May, down from CHF25m as at launch. Consequently CREALOGIX had 1,377,677 shares outstanding at 9 May, including the 170k issued for Innofis, along with CHF10,612,750 in convertibles corresponding to 101,557 voting rights. There were also 107,000 warrants outstanding, which represent 10,700 voting rights.

Exhibit 2: Balance sheet position

CHF000s

31/12/17

31/12/17

31/12/17

31/12/17

Book values

Acquisition of Innofis*

Pro forma

Assume all outstanding bonds convert

Cash & ST securities

(30,366)

11,068

(19,298)

(19,298)

Short-term borrowings

0

0

0

0

Long-term borrowings

0

0

0

0

Convertible bonds

14,054

0

14,054

0

Net cash

(16,312)

11,068

(5,244)

(19,298)

Assumed ELAXY FS&S deferred payment

2,387

2,387

2,387

Adjusted net debt (cash)

(13,925)

(2,857)

(16,911)

Net assets

41,464

25,416

66,880

80,934

Debt/equity

(33.6%)

(4.3%)

(20.9%)

Source: CREALOGIX Group. Note: *Cash purchase price less cash acquired, less transaction costs.

Forecasts: Innofis added, otherwise unchanged

The group recorded organic growth of 8% in H1, as we reported last month, but management expects this to accelerate in H2. Consequently, CREALOGIX maintained its mid-term guidance with annual sales growth of more than 20%, EBITDA of more than 15%, product sales of 70%+ of the total and international sales of 70%+. For FY18, CREALOGIX now expects 15% revenue growth, including a six-month contribution from Innofis, and at least a 10% EBITDA margin.

We note that the recent weakness in the Swiss franc against the euro provides a tailwind for revenues.

We have added Innofis and otherwise broadly maintained our forecasts. At the current exchange rate of CHF1.18/€, Innofis generated CHF11.5m of revenue in FY17 (vs reported CHF10.8m). We have conservatively assumed CHF5.8m for six months in FY18, growing at 10%, which translates to CHF12.7m in FY19 and CHF14.0m in FY20. We note that the numbers, particularly in the FY18 period, will be sensitive to new licence sales due to the traditional licence model. We have conservatively assumed operating margins of 32.5% for Innofis, which is below the historical levels, but we note that the margins have been declining.

Exhibit 3: The impact of adding Innofis

CHF000s

FY18

FY19

FY20

CREALOGIX continuing

Revenues

82,345

89,707

97,090

Costs

(73,766)

(78,787)

(84,307)

Operating profit

8,579

10,920

12,783

Operating margin (%)

10.4

12.2

13.2

Innofis

Revenues

5,768

12,691

13,960

Costs

(3,894)

(8,566)

(9,423)

Operating profit

1,875

4,124

4,537

Operating margin (%)

32.5

32.5

32.5

Combined

Revenues

88,113

102,398

111,050

Costs

(77,660)

(87,354)

(93,730)

Operating profit

10,454

15,044

17,320

Operating margin (%)

11.9

14.7

15.6

Source: Edison Investment Research

In all, we have increased our revenue forecasts by 7% in FY18 to CHF88.1m and 14% in each of FY19 and FY20 to CHF102.4m and CHF111.1m respectively. Our EBITDA forecasts increase by 20%, 35% and 34% to CHF11.8m, CHF16.4m and CHF18.7m, respectively. The acquisition boosts operating margins to rise by 140bp in FY18, 250bp in FY19 and 240bp in FY20. We have maintained our interest forecasts since the group maintains a healthy net cash position, and we also maintain our tax charge assumptions. We have ignored intangible amortisation at this stage. Our adjusted EPS (undiluted basis) increases by 10%, 12% and 14% in the respective years, tempered by the higher share count. Given the rise in the share price, convertible bonds have been actively converting. Hence we now forecast the group to end FY18 with net cash slightly higher at CHF19.2m, which rises to CHF27.8m a year later (previously CHF23.5m). Assuming that the remaining bonds convert will add CHF10.6m of net cash to the balance sheet. Consequently, the group has plenty of headroom to make additional bolt-on acquisitions.

Exhibit 4: Forecast changes

2018e

2019e

2020e

CHF000s

Previous

New

Change (%)

Previous

New

Change (%)

Previous

New

Change (%)

Revenues

 

 

 

 

 

 

 

 

 

Licensing fees

17,920

17,920

0

21,382

21,382

0

23,146

23,146

0

Maintenance

25,200

25,200

0

26,670

26,670

0

28,560

28,560

0

Hosting and SaaS services

7,560

7,560

0

10,800

10,800

0

14,580

14,580

0

Services

28,200

28,200

0

27,737

27,737

0

27,998

27,998

0

Goods

3,465

3,465

0

3,119

3,119

0

2,807

2,807

0

Innofis

 

5,768

N/A

 

12,691

N/A

 

13,960

N/A

Total group revenues

82,345

88,113

7

89,707

102,398

14

97,090

111,050

14

Growth (%)

10.0

17.7

77

8.9

16.2

81

8.2

8.4

3

Gross profit

67,198

72,101

7

74,814

85,601

14

82,428

94,294

14

Gross margin (%)

81.6

81.8

 

83.4

83.6

 

84.9

84.9

 

Opex before depn & amortisation

(57,319)

(60,273)

5

(62,645)

(69,157)

10

(68,445)

(75,624)

10

EBITDA

9,879

11,829

20

12,170

16,444

35

13,983

18,670

34

EBITDA margin (%)

12.0

13.4

 

13.6

16.1

 

14.4

16.8

 

Normal depreciation

(1,300)

(1,375)

6

(1,250)

(1,400)

12

(1,200)

(1,350)

13

Adjusted operating profit

8,579

10,454

22

10,920

15,044

38

12,783

17,320

35

Operating margin (%)

10.4

11.9

 

12.2

14.7

 

13.2

15.6

 

Growth (%)

45.0

76.7

 

27.3

43.9

 

17.1

15.1

 

Associates

250

250

0

263

263

0

276

276

0

Net interest

(750)

(750)

0

(650)

(650)

0

(100)

(100)

0

Profit before tax norm

8,079

9,954

23

10,532

14,657

39

12,959

17,495

35

Amortisation of acquired intangibles

(1,799)

(1,799)

0

(1,799)

(1,799)

0

(1,799)

(1,799)

0

Share-based payments

0

0

 

0

0

 

0

0

 

Exceptional items (net of tax)

0

(500)

 

0

0

 

0

0

 

Profit before tax

6,280

7,655

22

8,733

12,858

47

11,160

15,696

41

Taxation

(2,192)

(2,717)

24

(2,876)

(4,030)

40

(3,551)

(4,822)

36

Minority interest

(198)

(212)

7

(108)

(123)

14

(58)

(67)

14

Net income

3,890

4,726

21

5,750

8,704

51

7,550

10,808

43

Statutory EPS (CHF)

3.58

3.85

7

5.25

6.32

20

6.30

7.57

20

Adjusted EPS (CHF)

5.24

5.72

9

6.89

7.62

11

7.80

8.83

13

P/E - Adjusted EPS

 

28.5

 

21.4

 

18.5

Source: Edison Investment Research


Exhibit 5: Financial summary

CHF'000s

2015

2016

2017

2018e

2019e

2020e

Year end 30 June

Swiss GAAP

Swiss GAAP

Swiss GAAP

Swiss GAAP

Swiss GAAP

Swiss GAAP

PROFIT & LOSS

Revenue

 

49,307

63,317

74,858

88,113

102,398

111,050

Gross Profit

37,017

51,693

59,695

72,101

85,601

94,294

EBITDA

 

(10,555)

3,696

7,304

11,829

16,444

18,670

Adjusted Operating Profit

 

(11,815)

2,264

5,916

10,454

15,044

17,320

Amortisation of acquired intangibles

(1,616)

(2,634)

(1,799)

(1,799)

(1,799)

(1,799)

Exceptionals

0

0

0

(500)

0

0

Operating Profit

(13,431)

(370)

4,117

8,155

13,245

15,521

Associates

(837)

517

(21)

250

263

276

Net Interest

95

(630)

(936)

(750)

(650)

(100)

Profit Before Tax (norm)

 

(12,557)

2,151

4,959

9,954

14,657

17,495

Profit Before Tax (Statutory)

 

(14,173)

(483)

3,160

7,655

12,858

15,696

Tax

3,899

(130)

(1,751)

(2,717)

(4,030)

(4,822)

Profit After Tax (norm)

(8,658)

2,021

3,208

7,237

10,626

12,674

Profit After Tax (Statutory)

(10,274)

(613)

1,409

4,938

8,827

10,875

Minority interest

0

(270)

(360)

(212)

(123)

(67)

Net income (norm)

(8,658)

1,751

2,848

7,025

10,503

12,607

Net income (Statutory)

(10,274)

(883)

1,049

4,726

8,704

10,808

Average Number of Shares Outstanding (m)

1.06

1.06

1.07

1.23

1.38

1.43

EPS - normalised (CHF)

 

(8.13)

1.65

2.67

5.72

7.62

8.83

EPS - Statutory (CHF)

 

(9.65)

(0.83)

0.98

3.85

6.32

7.57

Dividend per share (CHF)

2.00

0.00

0.50

1.00

1.50

2.00

Gross Margin (%)

75.1

81.6

79.7

81.8

83.6

84.9

EBITDA Margin (%)

(21.4)

5.8

9.8

13.4

16.1

16.8

Op Margin (before GW and except.) (%)

(24.0)

3.6

7.9

11.9

14.7

15.6

BALANCE SHEET

Fixed Assets

 

20,371

28,910

26,430

56,401

54,585

52,991

Intangible assets and deferred tax

14,115

21,004

18,119

48,320

46,521

44,722

Tangible Assets

1,869

1,595

1,385

1,155

1,138

1,343

Investments & pensions

4,387

6,311

6,926

6,926

6,926

6,926

Current Assets

 

28,217

48,275

52,495

63,024

75,218

77,704

Stocks

3,447

3,661

3,419

4,024

4,677

5,072

Debtors

11,633

17,119

15,301

18,010

20,930

22,699

Cash

10,815

27,495

33,775

40,989

49,611

49,934

Current Liabilities

 

(19,183)

(24,752)

(24,219)

(28,052)

(54,055)

(34,987)

Creditors

(19,183)

(24,752)

(24,219)

(28,052)

(32,218)

(34,987)

Short term borrowings

0

0

0

0

(21,837)

0

Long Term Liabilities

 

(2,723)

(27,331)

(25,191)

(22,894)

(1,057)

(1,057)

Long term borrowings

0

(24,141)

(23,154)

(21,837)

0

0

Other long term liabilities

(2,723)

(3,190)

(2,037)

(1,057)

(1,057)

(1,057)

Net Assets

 

26,682

25,102

29,515

68,480

74,691

94,651

CASH FLOW

Operating Cash Flow

 

(4,503)

1,281

9,735

12,270

16,956

19,225

Net Interest

91

5

(616)

(750)

(650)

(100)

Tax

(269)

(144)

(1,273)

(1,178)

(2,687)

(3,957)

Capex

(1,018)

(486)

(862)

(1,145)

(1,382)

(1,555)

Acquisitions/disposals

(4,158)

(9,350)

(346)

(38,788)

(2,387)

0

Financing

925

1,504

(215)

27,387

0

0

Dividends

(2,126)

0

0

(954)

(1,227)

(2,067)

Net Cash Flow

(11,058)

(7,190)

6,423

(3,159)

8,622

11,547

Opening net debt/(cash)

 

(21,724)

(10,815)

(3,354)

(9,770)

(19,152)

(27,774)

Other

149

(271)

(7)

12,541

()

10,613

Closing net debt/(cash)

 

(10,815)

(3,354)

(9,770)

(19,152)

(27,774)

(49,934)

Source: CREALOGIX Group (historics), Edison Investment Research (forecasts). Note: The FY19 outflow represents the final payment for Elaxy FS&S. We have treated the convertible bond conversions in FY18 and FY20 in the Other category.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by CREALOGIX Group and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by CREALOGIX Group and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on CREALOGIX

View All

Latest from the TMT sector

View All TMT content

Research: Investment Companies

Biopharma Credit — Leading lender in life sciences

BioPharma Credit (BPCR) offers investors access to a diverse portfolio of secured debt instruments for life science companies based on BPCR’s pool of investment opportunities. The ongoing specialisation and fragmentation of the drug discovery process is translating into an increased number of market players seeking additional funding backed by sales from approved products and/or royalty streams from out-licensed products. During its IPO in March 2017 and follow-on placings, the trust has so far raised gross proceeds of US$1,080m (of which US$339m is in seed assets) and already deployed US$690m in four large deals. It also has outstanding potential commitments of up to US$350m.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free